Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1718156

registered interest
date	14/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the impact of the NHS England uniform pricing policy on patients' access to innovative medicines.
tabling member printed	Lord Warner
uin	HL4654
answer	answer is ministerial correction date of answer 21/05/2024 answer text <p>NHS England has successfully secured patient access to a number of innovative medicines under its policy of uniform pricing. European industry data from April 2023 showed that for every four treatments available in Europe, there is an additional medicine available in England, and a quarter more cancer drugs available in England compared to the European average.</p> answering member printed Lord Markham question first answered 21/05/2024 12:26:39 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1718157

registered interest
date	14/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government how many commercial agreements NHS England has made with manufacturers of medicines which allow, support or result in non-uniform pricing by individual medicine.
tabling member printed	Lord Warner
uin	HL4655
answer	answer is ministerial correction date of answer 21/05/2024 answer text <p>Since April 2020, NHS England has agreed to 37 commercial agreements that have resulted in non-uniform pricing by medicine, via either the Cancer Drugs Fund, or through bespoke commercial deals to support routine commissioning.</p> answering member printed Lord Markham question first answered 21/05/2024 12:26:52 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1681747

registered interest
date	11/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Standards
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government when was the last year that the NHS in England achieved (1) its four-hour target for A&E waiting times, (2) its 62-day target for cancer treatment, and (3) an average waiting time for elective surgery under six months.
tabling member printed	Lord Warner
uin	HL1544
answer	answer is ministerial correction date of answer 22/01/2024 answer text <p>The accident and emergency target and 62-day cancer treatment targets were last met at a national level in 2015. The average waiting time for elective surgery is currently under six months.</p> answering member printed Lord Markham question first answered 22/01/2024 17:25:20 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1681748

registered interest
date	11/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Standards
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what proportion of NHS acute hospital trusts in England met (1) their four-hour targets for A&E waiting times, and (2) their 62-day target for cancer treatment, in (a) 2009–10, and (b) 2022–23.
tabling member printed	Lord Warner
uin	HL1545
answer	answer is ministerial correction date of answer 14/02/2024 answer text <p>The information is not available in the format requested, as the National Health Service does not routinely report the proportion of providers meeting accident and emergency and cancer performance standards.</p> answering member printed Lord Markham question first answered 14/02/2024 12:22:41 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1681749

registered interest
date	11/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Surgery: Waiting Lists
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what proportion of NHS acute hospital trusts currently have average waiting times for elective surgery over six months; and what are the names of those trusts.
tabling member printed	Lord Warner
uin	HL1546
answer	answer is ministerial correction date of answer 22/01/2024 answer text <p>18 out of the 135, or 13.3%, of National Health Service trusts in England currently have an average waiting time for elective surgery of over six months. This has been defined as those NHS trusts with a median wait time for patients with a decision to admit that is over 26 weeks. Due to the size of the data, a spreadsheet is attached which includes a table listing the average waiting time for NHS trusts in England.</p> answering member printed Lord Markham question first answered 22/01/2024 17:03:10 answering member 4948 label Biography information for Lord Markham attachment 1 file name Copy of 150124 Trust Median Wait Times - HL1546.xlsx title HL1546 - Trust Median Wait Times
tabling member	1732 label Biography information for Lord Warner

1679265

registered interest
date	19/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Surgery: Working Hours
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what proportion of acute hospital trusts in England regularly conduct NHS operations on (1) Saturdays, and (2) Sundays; and whether this information is able to be published so that patients may exercise choice.
tabling member printed	Lord Warner
uin	HL1369
answer	answer is ministerial correction date of answer 27/12/2023 answer text <p>The information requested is shown in the attached table. This is existing Hospital Episode Statistics data that is already published by NHS England.</p> answering member printed Lord Markham question first answered 27/12/2023 13:05:54 answering member 4948 label Biography information for Lord Markham attachment 1 file name 11412_PQHL1369_suppressed (2).xlsx title Attachment
tabling member	1732 label Biography information for Lord Warner

1664761

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the proposed update to the 2023 Statutory Scheme to control the cost of branded health services medicines, what policy options were included in the Department of Health and Social Care's long list as alternatives to the options that were included in the final consultation.
tabling member printed	Lord Warner
uin	HL10591
answer	answer is ministerial correction date of answer 24/10/2023 answer text <p>The statutory scheme consultation sets out the options under consideration. We are in the process of analysing the responses provided, including consideration of any alternative options proposed, and will update on our preferred policy approach later this year. A copy of the impact assessment is attached.</p> answering member printed Lord Markham question first answered 24/10/2023 12:17:36 answering member 4948 label Biography information for Lord Markham attachment 1 file name Statutory Scheme Impact Assessment.pdf title Statutory Scheme Impact Assessment
tabling member	1732 label Biography information for Lord Warner

1664762

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what is the evidence that the Department of Health and Social Care used to support the statement in the consultation on the Statutory Scheme to control the cost of branded health services medicines that investment in research and development in the UK was not a "net benefit".
tabling member printed	Lord Warner
uin	HL10592
answer	answer is ministerial correction date of answer 23/10/2023 answer text <p>The approach to assessing the potential impacts on investment within the statutory scheme’s impact assessment followed well-established precedent and is in line with the Green Book paragraphs 6.5 and 6.6. As such, the impact assessment considers spillover benefits of investment, with a literature review suggesting an estimated mean benefit of 34% of the overall investment, but does not account for these within the net present value calculation due to investment being one of several possible company responses to change in profitability.</p> answering member printed Lord Markham question first answered 23/10/2023 09:57:20 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1664763

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the proposed update to the 2023 Statutory Scheme to control the cost of branded health services medicines, what analysis and evidence the Department of Health and Social Care considered when it proposed to keep growth in the cost of branded medicines in real-terms decline, at 2 per cent a year.
tabling member printed	Lord Warner
uin	HL10593
answer	answer is ministerial correction date of answer 24/10/2023 answer text <p>2% allowed growth per annum represents an 80% rise in allowed growth compared to the 1.1% per annum which applied in the statutory scheme from 2019 to 2023. The proposal is consistent with the approach that underpinned the current statutory scheme’s 1.1% allowed growth, i.e., it equals the average allowed growth of the preceding voluntary scheme.</p><p>The proposed allowed growth rate considered multiple factors including the overall fiscal path. Furthermore, consideration of the pipeline of upcoming new treatments featured within our forecast growth in spend on new treatments and, ultimately, continued growth forecast in medicine sales.</p><p>Controlling growth at this level is considered to allow for a viable overall envelope for the statutory scheme more favourable for industry compared to the existing statutory scheme arrangements, whilst continuing to ensure that spend on branded medicines is affordable to the National Health Service.</p> answering member printed Lord Markham grouped question UIN HL10594 question first answered 24/10/2023 11:37:30 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1664764

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Proposed update to the 2023 Statutory Scheme to control the cost of branded medicines, whether the 2 per cent cap in growth in the cost of branded medicines was assessed against (1) inflation expectations, and (2) demographic pressures.
tabling member printed	Lord Warner
uin	HL10594
answer	answer is ministerial correction date of answer 24/10/2023 answer text <p>2% allowed growth per annum represents an 80% rise in allowed growth compared to the 1.1% per annum which applied in the statutory scheme from 2019 to 2023. The proposal is consistent with the approach that underpinned the current statutory scheme’s 1.1% allowed growth, i.e., it equals the average allowed growth of the preceding voluntary scheme.</p><p>The proposed allowed growth rate considered multiple factors including the overall fiscal path. Furthermore, consideration of the pipeline of upcoming new treatments featured within our forecast growth in spend on new treatments and, ultimately, continued growth forecast in medicine sales.</p><p>Controlling growth at this level is considered to allow for a viable overall envelope for the statutory scheme more favourable for industry compared to the existing statutory scheme arrangements, whilst continuing to ensure that spend on branded medicines is affordable to the National Health Service.</p> answering member printed Lord Markham grouped question UIN HL10593 question first answered 24/10/2023 11:37:30 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner